A Multicenter, Open-Label, Dose Escalation Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematologic Malignancies.
Phase of Trial: Phase I
Latest Information Update: 01 Dec 2011
At a glance
- Drugs Anti-HGF monoclonal antibody L2G7 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 01 Dec 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
- 01 Dec 2011 Actual patient number is 27 according to ClinicalTrials.gov.
- 01 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.